Premier Biomedical Realigns Business to Eliminate Convertible Debt, Cancel Reverse Split & Fund Covid-19 R&D
Press Release | 04/06/2020
JACKSON CENTER, PA / ACCESSWIRE / April 6, 2020 / Premier Biomedical, Inc. (OTCPINK:BIEI) announced a multi-faceted agreement to eliminate the Convertible Notes as an obligation of Premier, cancel the previously announced plans for a reverse split, and secure near-term funding for ongoing R&D into a potential cure for Covid-19 as well as Premier's Anti-Addiction Patch™.